Details up front: a sterility test · orforglipron.
This is a planning question. I know what my options are; I do not know how to weigh them.
What I want is the minimum viable version, which I suspect is smaller than what I would design.
What is the minimum version of this that is still defensible?
Twelve months is 52 weeks, so the budget is set by lot turnover, not by the price of a sterility test. Take one lot a quarter as the low case: 4 lots a year, so a test-every-lot policy is 4 assays and a test-every-third-lot policy is 2 once you round up. Take one lot a month as the high case: 12 lots, and the same two policies are 12 assays and 4. The spread between the cheapest and the dearest defensible policy is therefore about a factor of six across the same 52 weeks. Choose the policy before the first result. One chosen after a disappointing figure is a reaction to that figure, and it will not survive the second one. Then spend it where it changes a decision: over a year, one content assay on each new lot tells you more than four purity figures on the same lot, because purity and content are independent and only one of them changes your arithmetic.
The practical consequence is that spot-testing one vial from a new supplier is better than assuming they are all the same.
A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
To be exact about it, if the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.
Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.
Worth noting that thermal excursions during shipping affect different vials differently, so the lot may not be homogeneous even if it left the factory that way.
The practical summary: a lot number without a sampling statement is a lot number without meaning.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStated carefully, the single most misleading statement on a research-grade certificate is a lot number with no statement of how many vials from that lot were tested.
Published segregation failures show that even modern automated processes sometimes produce lots with measurable vial-to-vial variation.
Mechanically, under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.
The limitation is that you cannot know for certain without testing every vial, and you almost never can afford to do that.
Assume segregation is possible, and design your sampling to catch it if it exists.
edited 6 Mar 2026 by e_dziedzic — clarified the distinction between purity and content
Start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.
Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.
The part that matters: testing a vial that has been open in the lab for three months is testing aged material, not the fresh lot, and the result should be explicitly noted as a retest.
Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.
I would treat a "complies with" statement without sampling details as a claim rather than as evidence.
If testing multiple vials, state how many you tested and why you chose those vials.
If a lot has visibly segregated — some vials showing different appearance — then sampling the top and bottom of the shipment is worth doing.
The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.
One qualification: testing more vials gives better confidence, but at some point the cost outweighs the benefit.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Concretely, sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.
For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.
Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.
The caveat is that sampling is a trade-off between cost and confidence, and neither test nor assumption is cost-free.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.